Pharma Penny Stock Under Rs 50: Company Is Establishing A State-Of-The-Art R&D Center In Hyderabad To Enhance Its Capabilities
From Rs 43.42 per share (52-week low) to Rs 45.49 per share, the stock is up by 5 per cent.
Today, shares of Sigachi Industries Ltd gained 1.74 per cent to Rs 45.49 per share from its previous closing of Rs 44.71 per share. The company has a market cap of over Rs 1,500 crore and has delivered good profit growth of 25 per cent CAGR over the last 5 years.
Sigachi Industries Limited, a leading pharmaceutical company, is boosting its Research and Development (R&D) capabilities by establishing a state-of-the-art R&D Center in Hyderabad, India. This strategic move consolidates critical API development and analytical efforts under one roof, signifying the company's dedication to innovation and long-term growth. The initiative involves an investment of up to USD 1 million and is slated to begin immediately.
The new R&D Center is designed to optimize API production by integrating advanced systems and adhering to stringent global regulatory standards, ensuring high-quality outputs that meet international benchmarks. It will also drive sustainable growth by expanding Sigachi's development pipeline and accelerating R&D progress. A team of 15-20 skilled R&D scientists will be employed at the facility, dedicated to accelerating product development for regulated markets. Furthermore, the facility will streamline the pharma product portfolio, focusing on priority APIs and intermediates, and allow synergies for manufacturing cutting-edge APIs and regulatory filings under the same roof.
Sigachi is committed to revolutionizing API development by advancing synthesis and analytical processes to enhance quality and impact lives. To achieve this, the company is intensifying R&D investments to drive high-value innovation, aiming to fuel an additional six CEPs in the coming six months. These investments will support the development of existing and new molecules, reinforcing Sigachi’s long-term growth trajectory and ensuring sustained profitability and market leadership.
DSIJ’s 'Tiny Treasure' service recommends researched Small-Cap stocks with Inherent Growth Potential. If this interests you, do download the service details here.
About the Company
Sigachi Industries Limited, a publicly traded pharmaceutical company listed on NSE and BSE, is a global leader in providing high-quality excipients, vitamin-mineral nutrient blends, APIs, and O&M services. With over 35 years of industry expertise, Sigachi has built a strong reputation as a trusted partner for pharmaceutical and nutraceutical companies worldwide. They specialize in innovative solutions for food stability, fortification, and nutrition, offering tailored blends of vitamins, minerals, and other ingredients to meet the evolving needs of consumers. By utilizing advanced technologies like blending, encapsulation, and spray drying, Sigachi empowers food manufacturers to create products with superior taste, quality, and nutritional value, contributing to a healthier and happier world.
The company announced positive Quarterly Results (Q3FY25) and nine-month results (9MFY24). According to quarterly results, revenue increased by 26 per cent to Rs 139.42 crore, EBITDA increased by 45 per cent to Rs 35.19 crore and consolidated net profit increased by 33 per cent to Rs 21.35 crore in Q3FY25 compared to Q3FY24. In its nine-month results, revenue increased by 22 per cent to Rs 360.03 crore, EBITDA increased by 39 per cent to Rs 89.75 crore and consolidated PAT increased by 33 per cent to Rs 56.29 crore in 9MFY25 compared to 9MFY24.
From Rs 43.42 per share (52-week low) to Rs 45.49 per share, the stock is up by 5 per cent. Investors should keep an eye on this small-cap pharma stock.
Disclaimer: The article is for informational purposes only and not investment advice.